BioMérieux acquires Hybiome Biomedical to consolidate the ma

BioMérieux, the international leader in in vitro diagnostics, today announced the acquisition of a controlling stake in Suzhou Hybiome Biomedical Engineering Co. Ltd. The company announced in July 2018 that it had acquired a minority stake in Hybiome.
 
Founded in 2009, Suzhou Hybiome Biomedical Engineering Co. Ltd is headquartered in Suzhou, China, specializing in automated immunoassay. The company integrates research and development, production and sales, and provides comprehensive solutions for in vitro diagnostics (reagents, instruments and supporting software), and has been approved by the State Drug Administration (the State Food and Drug Administration).
 
Suzhou Hybiome Biomedical Engineering Co. Ltd. mainly operates two types of automated immunoassay systems (AE-180 and AE-240), using the latest Chemiluminescence Immunoassay (CLIA) technology, and testing nearly 80 items. Its AE-120 analyzer has recently been approved by the State Food and Drug Administration, further expanding the scope of testing products. Hybiome currently has about 1,000 installed machines, mainly used in medium-sized hospitals (100 to 500 beds). The market for immunoassays in China is about 2 billion euros and is growing at a rate of 20% to 25%. The Chinese market has witnessed the growing importance of domestic immunoassay product suppliers, especially in the secondary hospital market.
 
BioMérieux has been providing diagnostic solutions in China for more than 25 years and has accumulated considerable professional experience in the field of immunoassays. Its VIDAS® series products are used for high-value medical testing, and hospitals that have more than 500 beds in China and more Professional institutions (tertiary hospitals) are widely used.